Acute Toxicity and Prothrombotic Effects of Quantum Dots:
Impact of Surface Charge

Jorina Geys, Abderrahim Nemmar, Erik Verbeke, Monica Ratoi, Marc F. Hoylaerts, Benoit Nemery, and Peter H.M. Hoet

Background: Quantum dots (QDs) have numerous possible applications for in vivo imaging. However, toxicity data are scarce.

Objectives: To determine the acute in vivo toxicity of QDs with carboxyl surface coating (carboxyl-QDs) and QDs with amine surface coating (amine-QDs), we investigated the inflammatory properties, tissue distribution, and prothrombotic effects after intravenous injection.

Methods: We performed particle characterization by transmission electron microscopy and dynamic light scattering. Carboxyl-QDs and amine-QDs were intravenously injected in mice (1.44–3,600 pmol/mouse). At different time intervals, analyses included fluorescence microscopy, blood cell analysis, bronchoalveolar lavage, wet and dry organ weights, and cadmium concentration in various organs. We examined the prothrombotic effects in vivo by assessing the effect of pretreatment with the anticoagulant heparin and by measuring platelet activation (P-selectin), and in vitro by platelet aggregation in murine and human platelet-rich plasma exposed to QDs (1.44–1,620 pmol/mL).

Results: At doses of 3,600 and 720 pmol/mouse, QDs caused marked vascular thrombosis in the pulmonary circulation, especially with carboxyl-QDs. We saw an effect of surface charge for all the parameters tested. QDs were mainly found in lung, liver, and blood. Thrombotic complications were abolished, and P-selectin was not affected by pretreatment of the animals with heparin. In vivo, carboxyl-QDs and amine-QDs enhanced adenosine-5’-diphosphate–induced platelet aggregation.

Conclusion: At high doses, QDs caused pulmonary vascular thrombosis, most likely by activating the coagulation cascade via contact activation. Our study highlights the need for careful safety evaluation of QDs before their use in human applications. Furthermore, it is clear that surface charge is an important parameter in nanotoxicology.

Key words: blood cell analysis, coagulation, intravenous, in vivo, nanoparticles, platelet aggregation, quantum dots, surface charge, thrombosis, toxicity. Environ Health Perspect 116:1607–1613 (2008). doi:10.1289/ehp.11566 available via http://dx.doi.org/ [Online 18 July 2008]

Nanotechnology holds great promise in numerous fields, including medicine. However, concerns have been expressed about possible adverse effects of nanomaterials (Hoet et al. 2004; Oberdörster et al. 2005b; Xia et al. 2006). Although such concerns may have been exaggerated, they are not entirely without foundation (Maynard 2006), and it is fair to state that research and development of novel technologies, such as nanotechnology, often take place without much regard for potential harmful effects on the environment and/or human health (Maynard 2006). The medical applications of quantum dot (QDs) represent a case in point.

Nanosized QDs have specific properties—tunable emission wavelength, broadband absorption spectrum, and photostability—that make them ideal diagnostic probes for long-term in vivo and in vitro (multicolor) imaging (Ballou et al. 2004; Jaiswal et al. 2003; Larson et al. 2003; Medzit et al. 2005; Michalek et al. 2005; So et al. 2006) and site-specific targeting of drugs (Akerman et al. 2002; Gao et al. 2004; Stroh et al. 2005; Tada et al. 2007; Yu et al. 2007). The existing knowledge of the hazard of QDs is very incomplete, certainly compared with drugs or other chemical agents (Hardman 2006). Although the in vitro cytotoxicity of QDs has been studied (Derfus et al. 2004; Kirchner et al. 2005; Lovric et al. 2005a, 2005b; Shiohara et al. 2004), little or no attention has been paid to their potential in vivo toxicity (Ballou et al. 2004; Kim et al. 2004; Larson et al. 2003). Recently, some studies (Fischer et al. 2006; Gopee et al. 2007; Soo Choi et al. 2007; Yang et al. 2007) have investigated the biodistribution of QDs. However, most information on their in vivo toxicity—or the alleged lack of it—has been derived from studies that were not specifically designed to evaluate toxicity.

In the present study, we investigated the acute in vivo toxicity, including systemic and pulmonary inflammation, tissue distribution, and prothrombotic effects, of commercially available cadmium selenide/zinc sulfide (CdSe/ZnS) QDs. To assess the importance of surface charge, we studied QDs with different surface modifications [with carboxyl surface coating (carboxyl-QDs) or with amine surface coating (amine-QDs)]. We performed a detailed particle characterization, as has been recommended when studying the hazards of nanomaterials (Oberdörster et al. 2005a).

Various doses—within the range of those used for in vivo applications (Ballou et al. 2004; Gao et al. 2004; Kim et al. 2004; So et al. 2006)—were intravenously (iv) administered to mice. In the first set of experiments, we administered relatively high doses (3,600, 720, or 144 pmol/mouse) and performed analyses after 1 hr. In the second set of experiments, lower doses (144, 14.4, or 1.44 pmol/mouse) were injected, and toxic effects were assessed over time (1, 4, or 24 hr). Because initial observations showed that injected QDs affected hemostasis, with vascular thrombi being produced in the lung circulation, we investigated the effect of an anticoagulant (heparin) on thrombosis in vivo and the effect of QDs on murine and human platelet aggregation in vitro. To our knowledge, this is the first comprehensive evaluation of the in vivo toxicity, prothrombotic effects, and biodistribution of injected QDs.

Materials and Methods

Particle characterization. Type I EviTags (Evident Technologies, New York, New York, USA) are core/shell QDs consisting of CdSe/ZnS. We used Catskill green, carboxyl or amine modified QDs (carboxyl-QDs and amine-QDs, respectively), purchased in a solution of approximately 9 nmol/mL QDs (or 0.25 mg/mL QDs). To ensure the quality of the QDs, we ran all experiments within 3 months after purchase and kept QDs in dark and refrigerated conditions. For the first set of experiments (144–3,600 pmol/mouse), this...
solution was concentrated 10-fold through evaporation of the solvent; for the second set of experiments (1.44–144 pmol/mouse), we used the original solution.

Particle size and distribution of the original solution and the concentrated solution were measured by dynamic light scattering (DLS), using a Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd., Worcestershire, UK). To this end, 2 µL particles were dispersed in 800 µL water, Hanks’ Balanced Salt Solution (HBSS; Gibco, Merelbeke, Belgium), saline (0.9% NaCl), or medium Dulbecco’s Modified Eagle Medium (DMEM; Gibco). We performed three series of 15 measurements and calculated the average particle size. The zeta potential was calculated from electrophoretic mobility measurements in five series of 30 measurements (Malvern Zetasizer Nano-ZS; Malvern Instruments Ltd.). The isoelectric point (IEP) was determined in water by measuring the change in electrophoretic mobility as a function of pH: the solution to a pH of approximately 10 and acid was introduced—step by step—automatically by the Malvern Zetasizer. At each point, the zeta potential and size were measured. The IEP was calculated as the pH value when the charge around the particle becomes zero, that is, a net neutral surface charge. Sample preparation for transmission electron microscopy (TEM) consisted of placing a volume of 0.5 µL QDs on a TEM copper grids (400 mesh) with a holey carbon film. The grids were then dried for 2–3 hr in a desiccator under vacuum. TEM pictures were taken using a JEOL 2010 microscope (JEOL Ltd., Tokyo, Japan).

**Animals.** Male Balb/c mice (20–23 g; Janvier Co., Uden, The Netherlands) received an iv injection in the tail vein (5 cm from the tail end), while being held in a restraining device. A bolus injection of 40 µL sterile saline (0.9% NaCl) containing QDs or 40 µL saline (controls) was given using a plastic 0.3-ml syringe of U-100 insulin (BD Microfine; BD, Erembodegem, Belgium). We ran experiments on different days with the doses randomly organized, although we included at least one control each day. All experimental procedures were approved by the local ethical committee for animal experiments. Animals were treated humanely and with regard for alleviation of suffering.

**Experimental design.** In the first set of experiments, 1 hr after injecting QDs (144–3,600 pmol/mouse), we removed the lung, heart, liver, kidneys, spleen, and brain for analysis by fluorescence microscopy. At the same time point, for QDs doses of 144–720 pmol/mouse, blood was collected, a bronchoalveolar lavage (BAL) was performed (right lung), and the weight (and after drying) of left lung, heart, liver, kidneys, spleen, and brain were recorded. Furthermore, in these organs and in the blood, we measured the Cd concentration to assess the tissue distribution.

In a separate experiment, mice were pretreated with the anticoagulant heparin and a dose of QDs of 720 pmol/mouse was administered. One hour after injection, the blood was analyzed and the lung and liver were removed for evaluation by fluorescence microscopy. We performed flow cytometry to assess the expression of P-selectin on activated platelets.

In the second set of experiments, lower doses of QDs (1.44–144 pmol/mouse) were injected, and analyses were performed after 1, 4, and 24 hr: blood analysis, BAL, and wet and dry weight of left lung, liver, kidneys, and spleen. The Cd concentration was measured in lung, liver, and blood. We also performed in vitro platelet aggregation studies with human and murine platelet-rich plasma (PRP), as described below.

**Blood analysis.** At 1, 4, or 24 hr after administration of QDs, the animals were anesthetized with 1.2 mg/kg pentobarbital (Nembutal; Ceva Santé Animale, Brussels, Belgium), and a blood sample was taken from the retroorbital plexus, using a heparinized capillary tube (Na-heparin minicaps; Hirschmann Laborgeräte, VWR, Haasrode, Belgium) filled with 4% sodium citrate (Sigma, Bornem, Belgium). The blood was collected in a tube containing heparin (BD microtainer with heparin) and analyzed for red and white blood cells, with hematoxylin and eosin (H&E), and the other slice was prepared: one was stained with Diff-Quik method. We then analyzed the number of erythrocytes, platelets, and lymphocytes, monocytes, eosinophils, and basophils (Cell-Dyn system 3500; Abbott Laboratories, Louvain-la-Neuve, Belgium).

**Fluorescence microscopy.** Animals were sacrificed 1 hr after injection of the QDs, by intraperitoneal injection of 90 mg/kg pentobarbital (Nembutal). A full-body perfusion via the left ventricle (with open vena cava) using a pressure of 1 m H₂O was performed with 0% NaCl, followed by fixation with 4% formaldehyde (VWV, Haasrode, Belgium). We collected the organs and stored them separately in 4% formaldehyde for 24 hr and then in Sörensen buffer (Sigma). Pieces of each organ were embedded in paraffin wax and two sequential slices were prepared: one was stained with hematoxylin and eosin (H&E), and the other was not stained. Digital images were taken with an AxioCam HRc camera and AxioPlan microscope, both from Zeiss (Zaventem, Belgium).

**BAL and wet and dry organ weight.** After sacrificing the animals, the chest was opened and the left lung was clamped, removed, and weighed (wet weight). After drying the lung at 70°C, we determined the dry weight. We also determined the wet and dry weights of other organs.

The right lung was lavaged three times with 0.4 mL sterile saline (0.9% NaCl). The recovered BAL fluid was pooled and centrifuged (2,000 × g for 10 min, 4°C). For differential cell counts, 250 µL of the resuspended cells (200,000 cells/mL) was spun (1,400 × g for 6 min; Shandon Cytopsin 3; TechGen, Zellik, Belgium) onto microscope slides, air dried, and stained (Diff-Quik method). We then analyzed 3 × 100 cells for the presence of macrophages, eosinophils, neutrophils, or lymphocytes. We did not perform full-body perfusion in this part of the experiment.

**Assessing tissue distribution by measuring Cd concentration.** After a full-body perfusion with sterile 0.9% NaCl, organs were collected. After drying, the organs were dissolved in 3 mL ultrapure nitric acid 60% (Sigma) in a water bath at 80°C. The Cd concentration was measured by inductively coupled plasma–optical emission spectrometry (ICP-OES; Optima 3300DV; Perkin Elmer, Zaventem, Belgium). The detection limit was 0.002 mg Cd/L, but only measurements > 0.006 mg Cd/L were considered positive. We calibrated the instrument with ICP Multi Element Standard Solution IV CertiPur (Sigma) containing 0.5 mg/L or 5 mg/L Cd. Blanks containing only nitric acid were measured as a negative control. The Cd concentration in the tissues is expressed on a wet weight basis, with mean ± SD weights of 1.275 ± 0.170 g for liver and 0.128 ± 0.032 g for lung, thus resulting in a detection limit of 0.014 µg Cd/g wet weight in liver and of 0.140 µg Cd/g wet weight in lung. In the high-dose experiments, 240 ± 48 mL blood was collected with a detection limit of 0.075 µg Cd/mL blood; in the low-dose experiments, 676 ± 98 mL blood was collected, resulting in 0.027 µg Cd/mL blood as the detection limit. The correlation between the amount of QDs and the concentration of Cd was obtained through a standard curve (1.08–90 pmol QDs).

**Investigation of prothrombotic effects in vivo.** Hemostasis is subdivided into a primary and secondary cascade. The first refers to processes relating to platelet activation; the second, to processes of coagulation. Both processes are intertwined and occur to varying degrees in the arterial and venous circulation. We investigated whether the thrombosis was a result of activation of the coagulation cascade by administering QDs in mice pretreated with the anticoagulant heparin. Two minutes before iv injection of QDs (720 pmol/mouse; n = 3) or saline (n = 3), mice received an intraperitoneal injection of heparin (10 U, in 200 µL saline). One hour later, blood was sampled from the retroorbital plexus and cells were counted, as described above. After a full-body perfusion, we prepared the lung and liver of the mice for fluorescence microscopy, as described above. In addition, in the same animals, blood was collected to assess P-selectin as a measure of platelet activation. For this purpose, blood was collected from the retroorbital plexus, using a heparinized capillary tube filled with 4% saline (0.9% NaCl), and the weight (and after drying) of left lung, heart, liver, kidneys, spleen, and brain were recorded.
sodium citrate, into an Eppendorf tube containing 20 μg/mL hirudin. This blood sample (100 μL) was fixed for 1 hr at 4°C in 900 μL diluted CellFix solution (BD). The fixed blood was centrifuged for 5 min at 2,000 rpm, the pellet was resuspended in 1 mL phosphate-buffered saline (PBS), and centrifuged for 5 min at 1,200 rpm. The pellet was kept at 4°C until analysis, within 5 hr.

For the analysis, the pellet was resuspended in 70 μL PBS with 20 μL blocking rat serum and 10 μL of an anti-CD62P antibody (phycoerythrin-labeled rat anti-mouse P-selectin; Emfret Analytics, Würzburg, Germany), and incubated for 20 min in the dark. Immediately after dilution to 1 mL with PBS, the samples were acquired on a FACSCaliber flow cytometer (BD) and the presence of P-selectin was investigated whether the thrombosis resulted in the window of the platelets.

In vitro platelet aggregation tests. We investigated whether the thrombosis resulted from activation of platelets by performing platelet aggregation tests. We prepared PRP by centrifuging citrated blood from untreated Balb/c mice and from six human healthy volunteers (men) who had not taken drugs, as previously described (Freson et al. 2001; Oury et al. 2003). The platelet count was adjusted previously described (Freson et al. 2001; Oury et al. 2003). The platelet count was adjusted to 0.25 × 10^9 platelets/µL, via dilution in autologous plasma. We induced platelet aggregation, followed on a Chrono-log aggregometer (Kordia, Leiden, The Netherlands), with the agonist ADP (adenosine-5′-diphosphate), at 5 μM for murine platelet aggregation and 0.625, 1, or 1.5 μM for human platelet aggregation, depending on the response of the donor platelets to ADP. We added ADP 1 min after preincubation of the PRP with QDs and induction of stirring. We then added either carboxyl-QDs or amine-QDs to the plasma (1.44–1,620 pmol/mL). Tests were performed without ADP.

Statistical analysis. We analyzed differences between groups by one-way analysis of variance followed by Newman-Keuls test; the

Table 1. Physical characterization of the QDs.

| Vehicle   | Diameter (nm) | Polydispersity index | Zeta potential (mV) | IEP |
|-----------|---------------|----------------------|---------------------|-----|
| Aminie-QDs| 77.3          | 0.285                | −32.2               | pH 3.19 |
| Di Water  | 137           | 0.331                | −17.3               |     |
| Di Water ×10^b| 80.5         | 0.249                | −14.2               |     |
| HBSS      | 93.3          | 0.228                | −14.2               |     |
| Saline    | 79.8          | 0.234                | −12.0               |     |
| DMEM      | 35.9          | 0.495                | −57.7               | pH 1.71 |
| Carboxyl-QDs| 46.5          | 0.495                | −24.5               |     |
| Di water  | 104           | 0.352                | −35.2               |     |
| Di water ×10^b| 107         | 0.439                | −24.3               |     |
| HBSS      | 93.3          | 0.325                | −14.2               |     |
| Saline    | 79.8          | 0.234                | −12.0               |     |
| DMEM      | 107           | 0.439                | −24.3               |     |

DI, deionized.

*Average diameter from intensity distribution, measured by DLS. *The QDs were concentrated 10-fold through evaporation of the solvent. *Samples were polydispersed, with the coexistence of two/three particle sizes.

Figure 1. TEM of amine-QDs. The core/shell of the QDs can be seen as structured elements (arrowheads); the coating is spread as a layer over the whole grid. Bar = 5 nm.

Figure 2. Size distribution by intensity, measured with DLS, of amine-QDs (A) and carboxyl-QDs (B) in water (1), HBSS (2), saline (3), DMEM (4), or water after 10-fold concentration through evaporation of the solvent (5).

Figure 3. Fluorescence microscopy 1 hr after iv administration of QDs in mice. (A and B) Lung of mouse dosed with 3,600 pmol amine-QDs (A) or carboxyl-QDs (B). Arrows indicate fluorescent QDs in thrombi; note the difference in number of thrombi in (A) and (B). (C and D) Enlargement of thrombi (arrows) shown in (B). No platelets can be seen inside the thrombi in either nonstained sections (C) or H&E-stained sections (D); instead, fibrin fibers are present. (E) Liver of a mouse injected with 3,800 pmol amine-QDs; the arrows indicate QDs. (F) H&E staining of lung from a mouse pretreated with heparin and dosed with 720 pmol carboxyl-QDs shows complete absence of thrombi. Bars = 50 μm.
hydrodynamic diameter of approximately 40 nm. We found that the amine-QDs and carboxyl-QDs differed in diameter and polydispersity index, depending on the vehicle. Moreover, when we concentrated the QDs 10-fold, the particles tended to aggregate, and this was more pronounced with carboxyl-QDs than with amine-QDs, as illustrated in Figure 2. Both QDs have a negative zeta potential in all tested vehicles, but the carboxyl-QDs are 2-fold more negative than the amine-QDs (Table 1).

The core of the QDs consists of CdSe. Measurements in two different batches of particles revealed that approximately 27% of the QD mass consists of Cd (0.833 µg/mL QDs contains 0.23 mg/L Cd). The linear correlation (R² = 0.9997) between Cd and QD concentration enables a quantification of the QDs in blood or tissues, down to 2.52 pmol.

**High doses of QDs: analysis 1 hr after injection.** After iv injection of 3,600 pmol/mouse of carboxyl-QDs, three out of four mice died immediately; no deaths were recorded after injection of amine-QDs. After iv injection of 720 or 144 pmol/mouse, all mice showed signs of discomfort, such as labored breathing and piloerection, but no deaths occurred.

Fluorescence microscopy revealed that particles were present in the lung and liver. Moreover, thrombi containing fluorescent QDs were apparent in the lung (Figure 3A,B). The number of thrombi was manifestly higher in animals injected with carboxyl-QDs than in those injected with amine-QDs. We found fewer thrombi at lower doses. H&E staining showed the presence of fibrin-rich thrombi in the lung circulation (Figure 3C,D). Fluorescent spots could also be found in the liver of mice treated with 3,600 pmol amine-QDs, but not at lower doses, and not with carboxyl-QDs (Figure 3E). We found no evidence of thrombi when the mice had been treated with heparin before injection of QDs (720 pmol; Figure 3F).

One hour after dosing with 720 pmol/mouse of carboxyl-QDs, the platelet count was significantly reduced (Figure 4A). With amine-QDs, we saw only a slight decrease, reaching significance for 144 pmol/mouse. No changes occurred in total blood leukocyte numbers or in the percentages of neutrophils, lymphocytes, or monocytes (data not shown). In the BAL fluid, we found no influx of neutrophils or lymphocytes (data not shown). The wet and dry weights of the organs of mice injected with QDs were not different from those of controls (data not shown).

Pretreatment with heparin before injection of 720 pmol QDs abolished the drop in platelet count (Figure 4A). Flow cytometry showed that the platelet P-selectin levels in mice injected with QDs did not differ from those in control mice (data not shown); that is, we saw no evidence of in vivo platelet activation in the presence of heparin.

The Cd concentration was below the detection limit in all the collected organs of control animals. In animals treated with QDs, the Cd concentration in lung and liver was dose-dependently increased (Figure 4B,C). We found up to 15 µg Cd/g lung in animals that received 720 pmol of carboxyl-QDs, corresponding to 39% of the initial injected dose (Table 2). Animals dosed with 144 pmol carboxyl-QDs had a mean Cd content of 0.37 µg/g lung (a total of 0.048 µg Cd in lung), corresponding to 4% of the initial injected dose. The amount of Cd in the lungs of animals receiving amine-QDs was lower. In the liver, we found higher amounts of amine-QDs compared with carboxyl-QDs: 0.90 µg Cd/g liver and 0.33 µg Cd/g liver for 720 and 144 pmol amine-QDs, respectively, corresponding to 24% and 34% of the administered dose. In the blood, we found Cd only in mice that received amine-QDs (Figure 4D, Table 2). In the other organs tested, Cd concentrations were below the detection limit (data not shown).

**Low doses of QDs: analysis at different time points.** To further assess toxicity over time (1, 4, and 24 hr), we selected doses that did not elicit noticeable acute symptoms in the mice (1.44–144 pmol/mouse). These doses are in the range of those used for in vivo applications (Kim et al. 2004; So et al. 2006).

These doses did not decrease the number of platelets (data not shown). However, the percentage of neutrophils in blood significantly increased from 20% to 47% 4 hr after injecting 144 pmol of carboxyl-QDs; in parallel, the percentage of lymphocytes decreased from 75% to 48% (Figure 5). Absolute numbers of neutrophils significantly increased 1 hr after administering 144 pmol amine-QDs (2.77 ± 0.70 × 10⁹/µL vs. 1.54 ± 0.43 × 10⁹/µL neutrophils in controls, p < 0.05) and 4 hr after 144 pmol carboxyl-QDs (2.40 ± 0.98 × 10⁹/µL vs. 1.42 ± 0.28 × 10⁹/µL neutrophils in controls; p < 0.05). The number of monocytes was increased 4 hr after injecting 144 pmol carboxyl-QDs (0.46 ± 0.33 × 10⁹/µL vs. 0.17 ± 0.13 × 10⁹/µL monocytes.

---

**Table 2. Cd measurement 1 hr after iv administration of carboxyl-QDs or amine-QDs (144 or 720 pmol/mouse).**

| Dose (pmol/mouse) | Lung | Liver |
|-------------------|------|-------|
|                   | Total Cd (µg) | Percent | Total Cd (µg) | Percent | Blood (%) |
| Carboxyl-QDs      |      |       |      |       |          |
| 144               | 0.048 ± 0.042 | 4.4 ± 3.8 | 0.054 ± 0.028 | 4.9 ± 2.6 | ND² |
| 720               | 2.152 ± 0.386 | 39.1 ± 7.1 | 0.214 ± 0.017 | 3.9 ± 0.3 | ND² |
| Amine-QDs         |      |       |      |       |          |
| 144               | 0.043 ± 0.018 | 3.9 ± 1.7 | 0.377 ± 0.058 | 34.3 ± 5.2 | 2.3 ± 0.6 |
| 720               | 0.606 ± 0.500 | 11.0 ± 9.1 | 1.315 ± 1.227 | 23.9 ± 2.23 | 1.3 ± 0.3 |

ND, not detectable. Values are mean ± SD from two to three animals.

*Total Cd in organ. *Percentage of the injected Cd dose. *< 0.006 mg/L Cd.

---

**Figure 4.** Effects and tissue distribution 1 hr after iv administration of carboxyl-QDs or amine-QDs (144 or 720 pmol/mouse). ND, below detection limit of 0.006 mg/L Cd. (A) Number of platelets in blood. Open squares and circles represent mice pretreated with heparin. (B–D) Tissue distribution based on the concentration of Cd in lung (B), liver (C), and blood (D). Horizontal bars represent the means. Blood analysis: control, n = 9; treatment, n = 4–5. Lung and liver analysis: control, n = 4; treatment, n = 2–3. *p < 0.05, *p < 0.001.
Cd was detected in the liver of mice that received 144 or 14.4 pmol QDs (Figure 6A), whereas a dose of 1.44 pmol did not result in detectable amounts of Cd. For amine-QDs, the amount of Cd in the liver was higher after 24 hr (1.121 ± 0.251 total μg Cd, after injection of 144 pmol amine-QDs) than after 1 hr (0.237 ± 0.325 total μg Cd). For carboxyl-QDs, the amount of Cd in liver did not change over time (for 144 pmol carboxyl-QDs, 0.898 ± 0.291 total μg Cd after 24 hr vs. 0.904 ± 0.260 total μg Cd after 1 hr). In the blood, we found excess Cd only in mice that received amine-QDs, and the concentration decreased over time (Figure 6B). In the lung, we found no Cd (data not shown).

**In vitro platelet aggregation tests.** To investigate whether human and murine platelets can be activated by QDs, we performed aggregation studies in PRP. The ADP-induced aggregation of murine PRP was dose-dependently enhanced upon preincubation for 1 min with amine-QD concentrations > 180 pmol/mL (Figure 7A,C). The effect of carboxyl-QDs on ADP-induced platelet aggregation was also dose dependent and even more pronounced. At 180 pmol/mL, platelet aggregation was elevated, leading to maximal platelet aggregation starting at 540 pmol/mL carboxyl-QDs (Figure 7B). Even a low dose of 144 pmol/mL carboxyl-QDs enhanced ADP-induced platelet aggregation; the lowest doses (14.4 and 1.44 pmol/mL) had no effect (Figure 7D). The particles themselves (amine-QDs or carboxyl-QDs) did not cause platelet aggregation in the absence of ADP. However, carboxyl-QDs induced a platelet shape change at a concentration of 1,620 pmol/mL (Figure 7E).

Human PRP aggregation was more variably affected by QDs. Blood from four of six donors
reacted on incubation with 720 pmol/mL amine-QDs with a mean 2.6-fold increase in maximal platelet aggregation amplitude, compared with control conditions without QDs; at 360 pmol/mL, only two of six donors responded, with a mean 1.7-fold increase. At lower concentrations, we noted no response. In the case of carboxyl-QDs, for one donor’s sample, the platelet aggregation was enhanced 3- or 4-fold at 144 or 14.4 pmol/mL, respectively. At 360 and 720 pmol/mL, four donors responded with a mean 2.6- and 3.7-fold increase, respectively. Figure 8A–D shows the platelet aggregation profile for one volunteer.

**Discussion**

Despite industrial and medicinal promise of nanomaterials, concerns have been expressed about their possible adverse health effects (Hoet et al. 2004; Oberdörster et al. 2005b; Xia et al. 2006). Because nanosized QDs are monodispersed and fluorescent, they can be used as good models for testing potential nanotoxicity. To study the influence of surface charge, we used commercially available type I EviTags, with either carboxyl or amine coatings; QDs of this type with neutral surface charge are not available. Because this is the first in-depth study specifically designed to test the in vivo toxicity of QDs, our purpose was to assess acute effects and to provide a dose–response relationship, together with an assessment of the tissue distribution, to identify the important target organs. Because vascular thrombi were produced in the lung, we investigated whether this thrombosis was due to either platelet activation or activation of coagulation. We examined platelet activation by assessing the effects of administering QDs on levels of P-selectin on circulating platelets (using flow cytometry) and by measuring platelet aggregation upon in vitro incubation of murine and human PRP with QDs. The role of coagulation was assessed by examining the effects of pretreatment with the anticoagulant heparin.

Experts have recommended characterizing essential physicochemical properties of nanoparticles whenever performing toxicity studies with nanomaterials (Oberdörster et al. 2005a). TEM is considered a gold standard for evaluating particle size distribution and shape (Oberdörster et al. 2005a). However, no satisfying TEM images could be obtained for the QDs used. The coating of the QDs was spread over the grid, covering the core/shell of the QDs, which is in line with findings of others (Fischer et al. 2006; Gopee et al. 2007; Soo Choi et al. 2007; Zhu et al. 2007). The separation of the coating from the core/shell of the QDs is thought to be due to the sample preparation process, including drying of the samples. As a consequence, no valuable data about aggregation and size could be obtained with this method. Nevertheless, sizes can be measured in solution using DLS. This method indicated that the amine-QDs were not aggregated, whereas the carboxyl-QDs were polydispersed in water (with the coexistence of two or three particle sizes) but almost monodispersed in the other tested vehicles. The zeta potential varied in the different vehicles: −14.2 mV for amine-QDs and −35.2 mV for carboxyl-QDs when dispersed in saline.

Because of their unique properties, QDs are considered ideal probes for in vivo imaging; low quantities (ranging from 300 pmol/g down to 0.01 pmol/g) are needed for in vivo applications (Ballou et al. 2004; Gao et al. 2004; Kim et al. 2004; Larson et al. 2003; So et al. 2006; Stroh et al. 2005; Tada et al. 2007; Yu et al. 2007). To establish realistic dose–response relationships, we tested concentrations from 3,600 pmol down to 1.44 pmol.

Three of four animals that received 3,600 pmol carboxyl-QDs died immediately upon injection because of massive thrombosis in the pulmonary vasculature. We also saw thrombi containing QDs in the lung of animals receiving 720 or 144 pmol carboxyl-QDs, and the number of thrombi was proportional to the dose administered. Carboxyl-QDs proved more potent in inducing pulmonary vascular thrombosis than did amine-QDs. A parallel drop in the circulating platelet count was induced, which at first suggested the occurrence of activation of circulating platelets, with aggregates being retained in the pulmonary microvasculature. However, although ADP-induced platelet aggregation was elevated by QDs in vitro, direct platelet activation by QDs does not explain the in vivo thrombotic complications. Indeed, the QDs themselves did not induce platelet aggregation, although the carboxyl-QDs induced a platelet shape change at the highest concentration tested, indicative of at least some platelet activation. For both surface properties, we observed a dose-dependent stimulation of the ADP-triggered platelet aggregation, and it was more pronounced for the carboxyl-QDs. The significance of these in vitro observations is unclear, because in vivo thrombotic complications were observed at QD plasma concentrations below those required for platelet activation stimulation.

This led us to hypothesize that the thrombotic events were caused not by platelet activation but by activation of the coagulation cascade, especially because massive fibrin fibers...
were present in the pulmonary thrombi. We tested this hypothesis by pretreating the mice with the anticoagulant heparin. With such pretreatment, carboxyl-QDs no longer induced thrombosis in the lung; in addition, circulating treatment, carboxyl-QDs no longer induced were present in the pulmonary thrombi. We leading to fibrin formation and simultaneous platelet activation by thrombin, which is a potent agonist of platelet activation via PAR1 protease-activated receptors on platelets (Kataoka et al. 2003), which function is fulfilled by PAR4 receptors on mouse platelets. This explains the more pronounced effect of carboxyl-QDs compared with amine-QDs. In previous studies (Nemmar et al. 2002), we found that positively charged amine polystyrene nanoparticles enhanced the ADP-triggered platelet aggregation more strongly than did negatively charged carboxyl polystyrene nanoparticles. In contrast to the QDs used here, these polystyrene particles had no effect on coagulation tests (Nemmar et al. 2002). Those findings do not contradict our present data, where coagulation induction, rather than platelet activation, is triggered by the negatively charged QDs. Polystyrene beads have a different surface chemistry than do the presently studied QDs. Because fibrin fibers were present in the thrombi and because pretreatment with heparin abolished the thrombotic effects, we speculate that negatively charged QDs activate the coagulation cascade via contact activation. We saw an effect of surface charge in all the parameters tested. Lower doses of 14.4 pmol or 1.44 pmol did not elicit acute adverse effects. This is the first comprehensive evaluation of the hazard of injected QDs and emphasizes that surface charge is an important parameter in assessing nanotoxicty.

REFERENCES

Akerman ME, Chan WCW, Laaksonen P, Bhatia SN, Rusuolati E. 2002. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 99:12617–12621.

Ballou B, Lageman HM, Ernst LA, Bruchze MP, Waggoner AS. 2004. Noninvasive imaging of quantum dots in mice. Bioconjugate Chem 15:79–86.

Derfus AM, Chan WCW, Bhatia SN. 2004. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 4:11–18.

Fischer H, Liu L, Pang KS, Chan WCW. 2006. Pharmacokinetics of nanoscale quantum dots: in vivo distribution, sequestration, and clearance in the rat. Adv Funct Mater 16:1299–1305.

Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, et al. 2001. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 98:85–92.

Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. 2004. In vivo cancer targeting and imaging with semiconductor quantum dot nanotags. Nat Biotechnol 22:969–976.

Gopee NN, Roberts DW, Webb P, Coetzar CR, Sillitoe PH, Warbrinton AR, et al. 2007. Migration of intradermally injected quantum dots to sentinel organs in mice. Toxicol Sci 98:249–257.

Hardman R. 2006. A toxicologic review of quantum dots: toxicity data on physicochemical and environmental factors. Environ Health Perspect 114:165–172.

Hoet PHM, Nemmar A, Nemery B. 2004. Health impact of nanoparticles. [Letter]. Nat Biotechnol 22:119.

Jaiswal JK, Mattoussi H, Mauro JM, Simon SM. 2003. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 21:47–51.